tylvalosin
new
broadspectrum
thirdgener
macrolid
may
exert
varieti
pharmacolog
activ
report
antioxid
antiinflammatori
activ
raw
macrophag
mous
treat
lipopolysaccharid
lp
well
piglet
challeng
porcin
reproduct
respiratori
syndrom
viru
prrsv
tylvalosin
treatment
markedli
decreas
tnfa
level
vitro
vivo
lp
prrsvinduc
reactiv
oxygen
speci
ro
product
lipid
peroxid
mice
lung
tissu
reduc
tylvalosin
treatment
mous
acut
lung
injuri
model
induc
lp
tylvalosin
administr
significantli
attenu
tissu
injuri
reduc
inflammatori
cell
recruit
activ
evalu
phospholipas
activ
increas
express
lower
tylvalosin
consist
mous
result
tylvalosin
pretreat
attenu
piglet
lung
score
improv
growth
perform
normal
rectal
temperatur
piglet
model
induc
prrsv
furthermor
tylvalosin
attenu
ikba
phosphoryl
degrad
block
nfkb
transloc
result
indic
addit
direct
antimicrobi
effect
tylvalosin
exhibit
antiinflammatori
properti
attenu
acut
lung
injuri
suppress
nfkb
activ
elsevi
inc
right
reserv
complex
process
develop
ali
date
underli
mechan
ali
remain
elus
effect
regimen
avail
one
treatment
definit
improv
surviv
involv
reduc
volum
air
appli
lung
mechan
ventil
thu
new
strategi
still
requir
achiev
effect
treatment
ali
might
ultim
aid
clinic
therapi
patient
aliard
ali
ard
character
intens
pulmonari
inflammatori
respons
involv
polymorphonuclear
neutrophil
pmn
recruit
interstiti
edema
disrupt
epitheli
integr
lung
parenchym
injuri
pathogenesi
aliard
involv
disord
oxidantantioxid
inflammationantiinflamm
upregul
adhes
molecul
increas
product
chemokin
activ
pmn
contribut
lung
injuri
releas
inflammatori
cytokin
proteolyt
enzym
ro
proinflammatori
mediat
display
key
event
ali
may
repres
potenti
target
therapi
inflammatori
cytokin
interleukin
play
major
role
mediat
amplifi
aliard
stimul
chemotaxi
activ
neutrophil
pharmacotherapi
aim
block
specif
cytokin
tnfa
unsuccess
suggest
global
inhibit
cytokin
signal
network
may
requir
imped
lung
injuri
therefor
import
develop
novel
therapeut
approach
modul
balanc
proinflammatori
antiinflammatori
respons
restor
immun
homeostasi
addit
alveolar
epitheli
cell
function
barrier
integr
crucial
preserv
normal
ga
exchang
injuri
loss
epitheli
cell
may
lead
progress
aliard
understand
mechan
develop
ali
ard
essenti
develop
novel
therapeut
option
treat
syndrom
anim
model
experi
ali
use
provid
direct
mechan
relat
diseas
pathogenesi
provid
opportun
explor
new
innov
therapeut
target
therefor
differ
anim
model
experiment
lung
injuri
develop
mous
model
ali
could
establish
intraperiton
ip
tracheal
intranas
instil
lp
ventil
smoke
inhal
mice
lp
import
compon
cell
wall
gramneg
bacteria
often
use
establish
experiment
model
ali
ali
repres
state
excess
product
inflammatori
mediat
includ
cytokin
chemokin
adhes
molecul
lp
major
stimulu
releas
mediat
may
caus
pulmonari
damag
lead
ali
although
great
advanc
understand
pathophysiolog
ali
achiev
avail
therapi
reduc
mortal
increas
qualiti
life
survivor
although
mani
studi
focus
pathophysiolog
ali
done
rodent
rodent
differ
human
mani
way
especi
regard
lung
anatomi
behavior
inflammatori
mediat
cytokin
small
anim
model
though
use
largescal
econom
screen
new
method
limit
may
directli
relev
clinic
condit
howev
larger
anim
use
detail
studi
longer
period
essenti
clinic
trial
perform
compar
speci
pig
human
show
remark
anatom
physiolog
immunolog
similar
use
experiment
anim
studi
ali
human
share
symptom
pig
includ
fever
metabol
dysfunct
system
hypotens
pulmonari
hypertens
vascular
leakag
result
lung
edema
increas
proinflammatori
cytokin
includ
tnfa
likewis
dissemin
intravascular
coagul
dic
similar
endorgan
failur
observ
pig
human
also
pig
gentl
easi
feed
show
higher
surviv
rate
domest
pig
significantli
lower
cost
china
fact
support
idea
pig
serv
excel
anim
model
studi
pathogenesi
ali
ard
addit
pig
attract
attent
valuabl
preclin
model
medic
research
prrsv
member
famili
arterivirida
order
nidoviral
replic
lung
alveolar
macrophag
induc
sever
cytokin
includ
tnfa
involv
pulmonari
inflamm
respons
produc
influenzalik
ill
associ
respiratori
distress
young
piglet
therefor
prrsvinduc
respiratori
distress
piglet
may
novel
safe
anim
model
studi
ali
sinc
viru
zoonot
pathogen
unlik
sarscov
tylvalosin
fig
new
broadspectrum
thirdgener
macrolid
tylosin
deriv
modif
isovaleryl
acetylisovaleryltylosin
tartrat
molecul
weight
like
macrolid
compound
drug
increasingli
recogn
possess
broad
spectrum
biolog
activ
import
therapeut
applic
howev
detail
mechan
antiinflammatori
immunomodul
activ
tylvalosin
unclear
address
issu
current
studi
design
investig
effect
tylvalosin
lpsstimul
raw
macrophag
well
lp
prrsvinduc
ali
explor
underli
mechan
respons
activ
fig
chemic
structur
tylosin
tylvalosin
tyl
tilmicosin
til
tyl
acetyl
isovaleryl
tylvalosin
provid
eco
anim
health
london
unit
kingdom
tilmicosin
lp
escherichia
coli
bromid
mtt
n
ethylenediamin
dihydrochlorid
sulfanilamid
dichlorofluoresceindiacet
dcfh
da
purchas
sigma
chemic
co
st
loui
mo
usa
substrat
aminododecanoyl
snglyceryl
phosphatidylcholin
dbpc
echelon
bioscienc
salt
lake
citi
ut
usa
dulbecco
modifi
eagl
medium
dmem
fetal
bovin
serum
fb
penicillin
streptomycin
cell
cultur
use
obtain
invitrogengibco
grand
island
ny
usa
mous
tnfa
enzymelink
immunosorb
assay
elisa
kit
purchas
r
system
minneapoli
mn
usa
cayman
chemic
ann
arbor
mi
usa
myeloperoxidas
mpo
malondialdehyd
mda
detect
kit
provid
jiancheng
bioengin
institut
nanj
nanj
jiangsu
provinc
china
rabbit
mab
pikba
mous
mab
ikba
rabbit
mab
hrpconjug
goat
antirabbit
goat
antimous
donkey
antigoat
antibodi
purchas
cell
signal
technolog
beverli
usa
mous
mab
rabbit
mab
goat
mab
santa
cruz
biotechnolog
santa
cruz
ca
usa
chemic
reagent
grade
raw
macrophag
cell
line
obtain
american
type
cultur
collect
atcc
rockvil
md
maintain
dmem
supplement
heatinactiv
fb
mm
glutamin
antibiot
uml
penicillin
u
ml
streptomycin
humidifi
atmospher
co
cell
passag
use
experi
experi
macrophag
incub
presenc
absenc
variou
concentr
tylvalosin
tilmicosin
alway
ad
h
prior
lp
mgml
treatment
prrsv
isol
strain
fj
hb
gx
hn
jx
grown
cell
passag
use
studi
cell
cultiv
dmem
supplement
heatinactiv
fb
mm
glutamin
antibiot
uml
penicillin
uml
streptomycin
humidifi
atmospher
co
use
prrsv
product
titrat
femal
icr
mice
weigh
approxim
g
purchas
vital
river
laboratori
anim
technolog
co
ltd
beij
china
mice
hous
microisol
cage
receiv
food
water
ad
libitum
laboratori
temperatur
ae
rel
humid
mice
hous
day
adapt
environ
experiment
threeweekold
crossbr
piglet
herd
free
prrsv
measur
prrsv
serum
antibodi
titer
obtain
commerci
farm
hous
isol
room
anim
facil
supervis
veterinarian
throughout
durat
studi
anim
receiv
food
water
ad
libitum
piglet
number
eartag
acclimat
week
experi
laboratori
personnel
anim
caretak
involv
studi
blind
treatment
given
respect
group
anim
experi
approv
anim
care
use
committe
beij
institut
anim
husbandri
veterinari
medicin
china
academi
agricultur
scienc
beij
perform
accord
guid
care
use
laboratori
anim
publish
us
nation
institut
health
cell
viabil
evalu
mtt
assay
briefli
cell
ml
plate
densiti
cellsml
plate
co
incub
overnight
cultur
period
cell
wash
dmem
incub
ml
tylvalosin
differ
concentr
mgml
h
follow
stimul
ml
lp
mgml
total
volum
well
ml
concentr
tylvalosin
lp
four
time
dilut
final
h
lp
stimul
ml
mtt
solut
mgml
pb
ml
fresh
cultur
medium
ad
cell
incub
h
co
supernat
remov
ml
dmso
ad
well
dissolv
produc
formazan
crystal
extinct
measur
nm
use
micropl
reader
thermo
scientif
usa
cell
viabil
defin
rel
untreat
control
cell
ie
viabil
control
absorb
treat
sampl
absorb
control
tylvalosin
solubil
pb
dilut
dmem
prior
treatment
raw
cell
plate
onto
plate
cellswel
incub
presenc
either
lp
alon
mgml
lp
plu
tylvalosin
mgml
mgml
mgml
mgml
h
cellfre
supernat
subsequ
employ
proinflammatori
cytokin
assay
use
elisa
kit
follow
protocol
manufactur
nitric
oxid
product
cell
cultur
supernat
determin
griess
reaction
supernat
collect
mix
equal
griess
reagent
n
ethylenediamin
dihydrochlorid
h
sulfanilamid
concentr
h
po
vol
shaken
lightli
min
room
temperatur
last
absorb
valu
triplic
sampl
read
micropl
reader
use
test
wavelength
nm
nitrit
concentr
determin
use
dilut
sodium
nitrit
standard
prrsv
cultur
cell
treat
tylvalosin
mgml
collect
h
viral
infect
three
freezethaw
cycl
cultur
serial
dilut
ad
cell
confluenc
plate
dilut
ad
four
well
day
infect
tcid
calcul
reedmuench
method
experi
done
triplic
lpsinduc
intracellular
ro
gener
determin
cell
use
ro
sensit
fluoresc
dye
dcfh
da
observ
intracellular
ro
product
oxid
dcfh
da
near
confluent
cell
round
coverslip
plate
pretreat
tylvalosin
mgml
h
coincub
lp
mgml
dcfh
da
mm
min
cell
wash
twice
pb
intracellular
level
ro
analyz
microscopi
dcf
fluoresc
intens
determin
number
cell
randomli
select
area
cell
infect
prrsv
strain
hn
moi
indic
time
point
h
postinfect
pi
presenc
either
viru
alon
viru
plu
tylvalosin
mgml
cell
treat
dcfh
da
mm
min
wash
twice
pb
intracellular
level
ro
analyz
microscopi
dcf
fluoresc
intens
determin
number
cell
randomli
select
area
block
nonspecif
site
block
solut
wtvol
nonfat
dri
milk
membran
incub
specif
primari
antibodi
h
rt
overnight
membran
incub
addit
min
peroxidas
conjug
secondari
antibodi
room
temperatur
immunoact
protein
detect
use
enhanc
chemiluminesc
ecl
western
blot
detect
kit
pierc
rockford
il
usa
icr
mice
intragastr
administr
pb
without
tylvalosin
mgkg
h
prior
intraperiton
administr
lp
mgkg
rest
h
h
control
anim
produc
inject
pb
number
mice
use
treatment
ten
select
time
point
lp
administr
blood
collect
analysi
left
lung
use
collect
bronchoalveolar
lavag
fluid
balf
lavag
four
time
ml
pb
via
intratrach
rout
balf
sampl
centrifug
g
min
pellet
cell
total
cell
pool
resuspend
ml
pb
cell
count
use
hemacytomet
supernat
store
subsequ
analysi
protein
mpo
cytokin
level
differenti
cell
count
determin
use
cytolog
prepar
slide
prepar
cytospin
stain
diffquik
total
cell
count
microscopi
superior
lobe
right
lung
use
histopatholog
evalu
activ
analysi
inferior
lobe
right
lung
use
obtain
lung
wettodri
weight
wd
ratio
present
studi
lung
wettodri
weight
ratio
calcul
assess
tissu
edema
mice
euthan
h
lp
challeng
inferior
lobe
right
lung
blot
dri
weigh
place
oven
h
obtain
dri
weight
ratio
wet
lung
dri
lung
calcul
assess
tissu
edema
protein
concentr
supernat
balf
quantifi
use
bca
protein
assay
kit
evalu
vascular
permeabl
airway
level
tnfa
cellfre
balf
evalu
use
elisa
accord
manufactur
instruct
content
nitric
oxid
balf
determin
accord
colorimetr
method
describ
activ
mpo
determin
lung
tissu
commerci
kit
accord
manufactur
instruct
one
hundr
milligram
right
lung
tissu
n
homogen
fluidiz
extract
buffer
obtain
homogen
sampl
includ
ml
homogen
ml
reaction
buffer
heat
water
bath
min
enzymat
activ
determin
measur
chang
absorb
nm
use
micropl
reader
mda
concentr
determin
indic
lipid
peroxid
lung
tissu
tissu
sampl
lung
weigh
homogen
wv
moll
phosphat
buffer
ph
ice
bath
homogen
centrifug
g
min
subsequ
mda
content
supernat
measur
use
commerci
kit
protein
content
supernat
determin
bca
protein
assay
kit
concentr
mda
express
nanomol
per
milligram
protein
lung
tissu
shear
mix
ml
lysi
buffer
mm
hepe
sucros
ph
contain
proteas
inhibitor
cocktail
sigmaaldrich
st
loui
mo
usa
sampl
homogen
tissu
homogen
centrifug
g
min
supernat
remov
fresh
tube
small
aliquot
retain
protein
assay
activ
analyz
use
fluoresc
substrat
dbpc
fluorogen
phosphatidylcholin
pc
substrat
lung
tissu
homogen
mg
protein
mix
dbpc
mg
ml
pb
activ
express
chang
fluoresc
intens
per
minut
per
milligram
protein
h
h
treatment
left
lung
liver
isol
place
tube
contain
paraformaldehyd
pb
ph
incub
overnight
wash
three
time
tissu
process
prepar
paraffin
embed
cut
section
examin
inflammatori
aspect
lung
liver
section
process
hematoxylin
eosin
h
e
stain
section
airdri
gelatin
coat
slide
immers
hematoxylin
min
check
complet
stain
tap
water
eosin
stain
perform
min
section
dehydr
grade
seri
alcohol
ethanol
min
clear
xylen
mount
coverslip
stain
section
photograph
use
microscop
origin
magnif
six
section
sampl
evalu
score
independ
two
member
laboratori
train
histolog
assess
use
score
system
briefli
three
differ
lobe
examin
follow
featur
interstiti
edema
hemorrhag
neutrophil
infiltr
featur
could
receiv
score
injuri
minim
injuri
moder
injuri
sever
injuri
total
given
lobe
score
three
lobe
averag
gener
score
mous
give
minimum
score
maximum
deparaffin
section
sequenti
treat
hydrogen
peroxid
h
methanol
min
quench
endogen
peroxidas
rins
thoroughli
pb
section
block
normal
block
serum
pb
room
temperatur
min
suppress
nonspecif
bind
igg
follow
incub
mous
mab
rabbit
mab
rabbit
mab
goat
mab
rabbit
mab
pikba
mous
mab
ikba
respect
sampl
wash
pb
incub
min
room
temperatur
secondari
igg
dilut
normal
block
serum
incub
min
room
temperatur
avidinbiotinperoxidas
complex
abc
elit
kit
vector
laboratori
burlingam
ca
usa
sampl
wash
pb
incub
min
dab
sigmaaldrich
st
loui
mo
usa
hydrogen
peroxid
min
dark
assess
immunoreact
section
counterstain
eosin
mount
verifi
immunoreact
specif
mpo
ikba
pikba
section
also
incub
primari
antibodi
secondari
secondari
antibodi
primari
situat
posit
stain
found
section
indic
immunoreact
posit
experi
carri
slide
observ
microscop
immunocytochemistri
photograph
n
assess
densitometri
immunoreact
analyz
imag
pro
plu
softwar
media
cybernet
silver
spring
usa
person
comput
everi
section
integr
optic
densiti
iod
everi
visual
field
calcul
total
pig
eartag
randomli
alloc
n
group
pig
belong
medic
group
receiv
feed
contain
ppm
tylvalosin
day
day
postmed
group
pig
infect
ml
pernostril
prrsv
strain
hn
tcid
ml
four
group
pig
receiv
uninfect
cultur
supernat
similar
manner
serv
nonmed
nonchalleng
control
pig
challeng
pig
group
continu
receiv
tylvalosin
medic
feed
anoth
day
clinic
sign
rectal
temperatur
record
daili
blood
sampl
taken
day
postinocul
pi
sera
aliquot
store
later
analysi
anim
also
weigh
weekli
basi
pig
necropsi
end
experi
die
euthan
sever
ill
complet
necropsi
perform
pig
organ
examin
emphasi
respiratori
tract
lung
given
score
estim
percentag
lung
surfac
affect
use
score
system
previous
report
evalu
gross
lung
lesion
rtpcr
perform
sera
collect
day
pi
extract
viral
rna
perform
use
qiaamp
viral
rna
minikit
qiagen
valencia
ca
usa
describ
kit
instruct
rtpcr
assay
kit
prrsv
detect
purchas
takara
dalian
liaon
provinc
china
use
accord
kit
instruct
quantit
data
given
mean
valu
ae
sd
indic
analysi
differ
group
anova
follow
appropri
post
hoc
test
individu
comparison
group
perform
test
twotail
p
consid
statist
signific
level
tnfa
cultur
supernat
measur
use
elisa
kit
treatment
raw
cell
lp
alon
result
signific
increas
cytokin
product
compar
drug
group
fig
howev
level
tnfa
supernat
lp
stimul
cell
pretreat
mgml
tylvalosin
tilmicosin
reduc
significantli
compar
lp
group
dose
depend
manner
p
p
fig
signific
differ
tylvalosin
tilmicosin
addit
mtt
result
show
cell
viabil
affect
tylvalosin
concentr
use
mgml
data
shown
thu
effect
tylvalosin
cell
attribut
cytotox
effect
determin
level
cytokin
balf
balf
harvest
h
h
lp
challeng
tnfa
level
measur
elisa
proinflammatori
cytokin
level
balf
mice
treat
tylvalosin
mgkg
ig
significantli
increas
compar
lp
group
p
p
fig
lung
tissu
section
lpstreat
mice
demonstr
strong
posit
stain
tnfa
fig
b
mainli
local
epitheli
bronchial
cell
see
arrow
fig
inflammatori
cell
subbronchi
epitheli
see
arrow
fig
lymphocyt
see
arrow
fig
lp
treat
mice
receiv
tylvalosin
treatment
mgkg
ig
stain
tnfa
visibl
significantli
reduc
comparison
vehicletr
mice
fig
posit
stain
tnfa
found
lung
tissu
shamtreat
mice
fig
lp
administr
also
significantli
enhanc
product
indic
increas
nitritenitr
fig
stimul
cell
compar
ctrl
cell
stimul
lp
presenc
tylvalosin
tilmicosin
mgml
concentrationdepend
inhibit
gener
observ
fig
higher
concentr
mgml
significantli
inhibit
releas
special
tylvalosin
show
higher
inhibit
effect
releas
shown
fig
lp
ip
inject
significantli
increas
level
p
compar
ctrl
compar
lp
group
differ
dose
tylvalosin
decreas
product
balf
p
mgkg
p
mgkg
shown
antioxid
inhibit
nfkb
activ
signal
pathway
suppress
inflammationassoci
gene
express
macrophag
stimul
lp
decreas
intracellular
ro
level
test
whether
tylvalosin
inhibit
intracellular
ro
gener
cell
stimul
lp
tylvalosin
treatment
strongli
inhibit
lpsmediat
increas
intracellular
ro
level
dose
depend
manner
fig
c
tylvalosin
alon
effect
ro
product
data
shown
product
ro
subsequ
oxid
damag
cell
tissu
recogn
key
contributor
viral
pathogenesi
rosmedi
oxid
stress
could
also
contribut
prrsvinduc
apoptosi
current
studi
continu
upregul
gener
ro
observ
h
pi
h
pi
fig
ro
induc
prrsv
declin
h
pi
h
pi
gradual
tylvalosin
treatment
significantli
inhibit
prrsvmediat
increas
intracellular
ro
level
h
pi
h
pi
fig
lung
mda
level
indic
lipid
peroxid
increas
markedli
lp
group
compar
ctrl
group
fig
wherea
increas
significantli
attenu
tylvalosin
treatment
mgkg
ig
group
shown
fig
assess
local
injuri
respons
lp
detail
lung
liver
histolog
examin
perform
earli
h
lp
administr
mark
differ
lung
liver
injuri
observ
ctrl
lp
mice
shown
fig
perivascular
exud
thicken
alveolar
septa
hemorrhag
airspac
edema
hepatocyt
degener
apoptosi
necrosi
exhibit
mice
treat
lp
ip
mg
kg
notic
attenu
tylvalosin
treatment
p
mgkg
tylvalosin
p
mgkg
tylvalosin
mice
h
fig
consist
injuri
pattern
balf
protein
concentr
fig
lung
wet
dri
ratio
fig
increas
lp
treatment
mice
howev
treatment
tylvalosin
mgkg
mgkg
ig
markedli
decreas
lung
wd
ratio
p
p
total
protein
concentr
p
balf
mice
taken
togeth
find
indic
tylvalosin
attenu
local
system
respons
ip
lp
h
h
challeng
lp
inflammatori
cell
level
ie
total
cell
neutrophil
macrophag
lymphocyt
eosinophil
balf
significantli
elev
lpschalleng
mice
vs
ctrl
mice
fig
howev
tylvalosin
administr
mgkg
ig
p
mgkg
p
mgkg
decreas
total
cell
number
number
infiltr
neutrophil
macrophag
dosedepend
manner
fig
compar
lpschalleng
mice
mpo
activ
anoth
measur
lung
parenchym
phagocyt
infiltr
lp
challeng
result
signific
increas
lung
mpo
activ
compar
ctrl
group
p
tylvalosin
mgkg
ig
h
lp
exposur
significantli
reduc
mpo
activ
compar
lp
group
p
p
fig
result
consist
data
total
lavag
cell
count
percentag
lympocyt
neutrophil
balf
reduc
lpstreat
mice
receiv
mgkg
tylvalosin
compar
group
treat
lp
alon
fig
mpo
immunostain
result
also
support
data
fig
along
histopatholog
chang
ihc
reveal
inhibitori
effect
tylvalosin
activ
activ
lung
dab
stain
lung
demonstr
diminish
express
tylvalosin
fig
note
deep
stain
epitheli
bronchial
cell
see
arrow
inflammatori
cell
subbronchi
epitheli
see
arrow
leukocyt
dab
lpstreat
mice
interestingli
phenomenon
attenu
tylvalosin
mgkg
ig
significantli
higher
level
activ
found
homogen
lung
lpstreat
mice
compar
ctrl
mice
fig
activ
significantli
reduc
mice
tylvalosin
p
mg
kg
p
mgkg
ig
cytotox
effect
tylvalosin
cell
evalu
use
mtt
assay
result
show
tylvalosin
display
cytotox
effect
concentr
less
mgml
data
shown
inhibitori
effect
tylvalosin
prrsv
isol
infect
investig
tcid
viru
yield
reduct
assay
result
show
tylvalosin
abil
inhibit
differ
prrsv
isol
infect
cell
fig
viru
yield
reduct
tcid
increas
log
log
concentr
mgml
tylvalosin
fig
result
indic
prrsv
isol
sensit
tylvalosin
challeng
pig
group
show
clinic
sign
includ
redden
skin
inappet
lethargi
rough
hair
coat
dyspnoea
periocular
edema
eyelid
oedema
slightli
diarrhea
data
shown
similar
clinic
sign
low
intens
observ
group
anim
rectal
temperatur
taken
daili
challeng
prrsv
infect
anim
mean
temperatur
group
increas
group
day
pi
exceed
temperatur
consid
hyperthermia
day
pi
temperatur
significantli
higher
pig
group
b
day
pi
pig
group
show
slight
fever
littl
fluctuat
rectal
temperatur
day
pi
fig
mean
temperatur
group
remain
experi
viraemia
determin
rtpcr
serum
sampl
anim
neg
viral
rna
dpi
anim
group
remain
neg
throughout
studi
result
encourag
enough
merit
work
studi
phenomenon
viral
rna
detect
virusinfect
group
day
pi
four
anim
day
pi
day
pi
assess
gross
clinic
effect
tylvalosin
medic
swine
anim
weigh
time
point
data
averag
daili
weight
gain
adwg
deriv
day
pi
inocul
day
pi
fig
challeng
dpi
slight
weight
increas
pig
group
although
signific
p
challeng
group
show
significantli
reduc
adwg
compar
anim
group
addit
group
statist
signific
higher
adwg
group
signifi
tylvalosin
significantli
reduc
anim
growth
challeng
postmortem
lung
examin
gross
patholog
given
score
depend
percentag
lung
surfac
affect
gross
lesion
maximum
point
group
averag
highest
score
around
surfac
lung
affect
lesion
fig
lowest
mean
score
seen
group
follow
around
surfac
lung
affect
lesion
nonmed
nonchalleng
anim
group
euthan
show
signific
patholog
phosphoryl
ikb
subunit
nfkb
import
event
transloc
transcript
activ
nfkb
unstimul
cell
nfkb
local
cytosol
due
bind
ikb
activ
lp
ikb
phosphoryl
ikb
kinas
degrad
releas
nfkb
transloc
nucleu
therefor
activ
nfkb
assess
cell
measur
degre
phosphoryl
ikba
protein
nfkb
transloc
treatment
lp
result
degrad
ikba
degrad
significantli
block
tylvalosin
fig
b
determin
whether
ikba
degrad
relat
ikba
phosphoryl
examin
effect
tylvalosin
lpsinduc
pikba
western
blot
result
show
phosphoryl
ikba
cell
increas
lp
administr
significantli
inhibit
tylvalosin
concentr
depend
manner
fig
b
gain
insight
mechan
tylvalosinmedi
regul
nfkb
examin
effect
tylvalosin
nfkb
nuclear
transloc
shown
fig
lpstreat
cell
show
notabl
increas
nuclear
protein
level
decreas
cytoplasm
protein
level
compar
pbstreat
cell
tylvalosin
treatment
significantli
attenu
alter
dosedepend
manner
p
p
determin
effect
tylvalosin
treatment
vivo
activ
classic
nfkb
pathway
lung
tissu
section
mice
analyz
pikba
ikba
ihc
shown
fig
ihc
analysi
reveal
pikba
stain
intens
higher
lp
group
compar
ctrl
anim
predominantli
local
within
cytosol
treatment
tylvalosin
reduc
number
pikba
stain
intens
compar
lp
group
fig
revers
case
ikba
fig
quantit
analysi
show
significantli
decreas
express
pikba
increas
express
ikba
lung
mice
treat
tylvalosin
mgkg
ig
fig
tylvalosin
new
broadspectrum
antibiot
belong
thirdgener
macrolid
use
studi
evalu
whether
tylvalosin
exert
antiinflammatori
effect
lpsstimul
raw
cell
anim
model
ali
collect
result
investig
demonstr
tylvalosin
inhibit
inflamm
reduc
express
proinflammatori
mediat
normal
regul
nfkb
pathway
well
downregul
ro
result
indic
tylvalosin
might
potenti
new
therapeut
agent
prevent
treatment
inflammatori
diseas
assess
pharmacolog
biolog
effect
tylvalosin
product
proinflammatori
cytokin
lpsstimul
raw
macrophag
role
tylvalosin
suppress
product
proinflammatori
cytokin
blockag
nfkb
signal
pathway
examin
result
demonstr
tylvalosin
inhibit
secret
tnfa
dose
depend
manner
fig
tylvalosin
tilmicosin
semisynthes
compound
deriv
tylosin
belong
macrolid
consist
previou
studi
present
studi
also
shown
tilmicosin
significantli
decreas
product
twentyfour
hour
lp
inject
lp
mice
continu
sever
lung
liver
injuri
tylvalosin
p
mgkg
treat
mice
origin
magnif
e
lp
treatment
mice
sever
lung
liver
injuri
histolog
score
h
base
hemorrhag
interstiti
edema
inflammatori
cell
infiltr
hepatocyt
degener
apoptosi
necrosi
total
balf
protein
concentr
f
wet
dri
ratio
g
increas
lp
mice
ip
lp
compar
ctrl
mice
tylvalosin
treatment
mice
n
group
replic
time
histolog
wet
dri
balf
protein
p
p
histolog
score
three
mice
per
group
three
lobe
examin
per
mous
tnfa
taken
togeth
find
report
suggest
like
macrolid
macrolid
also
antiinflammatori
activ
apart
antibacteri
activ
product
tnfa
differ
tylvalosin
tilmicosin
treatment
result
indic
antiinflammatori
activ
depend
parent
ring
lacton
ring
fig
seem
noth
side
chain
modif
howev
tylvalosin
even
lower
concentr
show
higher
inhibit
effect
releas
compar
tilmicosin
differ
could
attribut
tylvalosin
side
chain
modif
oisovaleryl
furthermor
tylvalosin
exhibit
rapid
entri
accumul
tilmicosin
tylvalosin
rapidli
metabol
metabol
within
min
main
metabolit
possess
equival
activ
parent
compound
inform
gain
studi
could
use
design
develop
novel
macrolid
agreement
vitro
result
found
tylvalosin
play
potent
antiinflammatori
role
lpsinduc
ali
mice
tylvalosin
significantli
attenu
lp
stimul
pulmonari
morpholog
chang
lung
edema
alveolar
hemorrhag
inflammatori
cell
infiltr
fig
apart
lung
exposur
human
anim
excess
amount
lp
also
caus
liver
injuri
kupffer
cell
mediat
lpsinduc
inflammatori
respons
liver
present
studi
suggest
tylvalosin
also
significantli
attenu
lp
stimul
liver
morpholog
chang
hepatocyt
degener
apoptosi
necrosi
data
indic
tylvalosin
could
attenu
system
inflamm
induc
lp
quantifi
magnitud
pulmonari
edema
evalu
wd
ratio
lung
experi
shown
tylvalosin
may
significantli
inhibit
edema
lung
indic
wd
ratio
tylvalosin
group
significantli
lower
lp
group
fig
anoth
index
ali
lp
measur
total
protein
concentr
balf
fig
indic
epitheli
permeabl
pulmonari
edema
expect
lp
inject
found
caus
signific
increas
balf
protein
concentr
lpsinduc
increas
total
protein
balf
inhibit
tylvalosin
inflammatori
cell
count
balf
reflect
extravas
predomin
inflammatori
cell
neutrophil
play
import
role
develop
case
ali
may
repres
potenti
target
therapi
consequ
address
effect
tylvalosin
treatment
ali
neutrophil
effector
function
addit
involv
neutrophil
macrophag
known
play
crucial
role
lpsinduc
ali
studi
mice
expos
lp
exhibit
massiv
recruit
inflammatori
cell
includ
neutrophil
macrophag
fig
contrast
pretreat
tylvalosin
inhibit
increas
number
total
cell
neutrophil
macrophag
balf
addit
lung
histolog
examin
fig
also
support
find
infiltr
proinflammatori
cell
hemorrhag
format
hyalin
membran
alveolar
edema
airway
epitheli
necrosi
found
common
promin
lp
group
rare
tylvalosin
mgkg
ig
treatment
group
result
suggest
protect
effect
tylvalosin
ali
relat
attenu
inflammatori
cell
sequestr
migrat
lung
tissu
neutrophil
recruit
lung
involv
cascadelik
fashion
activ
intravascular
accumul
transendotheli
transepitheli
migrat
differ
adhes
molecul
chemokin
involv
neutrophil
recruit
therefor
detail
mechan
tylvalosin
inhibit
activ
neutrophil
recruit
activ
need
studi
exist
increas
mpo
activ
infiltr
neutrophil
lung
ali
mpo
activ
marker
neutrophil
influx
tissu
directli
proport
temperatur
consid
febril
data
repres
mean
ae
sd
c
growth
effect
tylvalosin
swine
experiment
pig
weigh
day
end
studi
averag
daili
weight
gain
adwg
five
pig
group
calcul
period
dpi
data
repres
mean
ae
sd
tylvalosin
medic
effect
lung
lesion
score
anim
sacrif
dpi
lung
score
gross
patholog
gross
patholog
data
repres
mean
ae
sd
signific
indic
p
p
number
neutrophil
tissu
studi
present
data
illustr
increas
mpo
activ
lung
tissu
lpsinduc
ali
model
consist
mpo
immunostain
result
histopatholog
chang
leukocyt
infiltr
increas
significantli
reduc
two
dose
mgkg
tylvalosin
fig
e
studi
demonstr
pretreat
tylvalosin
significantli
improv
ali
mice
relat
attenu
inflammatori
cell
sequestr
migrat
lung
tissu
addit
signific
reduct
neutrophil
balf
lung
tissu
infiltr
follow
activ
decreas
discuss
result
suggest
attenu
lpsinduc
ali
tylvalosin
might
relat
modul
antioxid
strategi
regul
intracellular
level
ro
attenu
lung
inflammatori
injuri
extens
investig
also
result
current
studi
show
tylvalosin
suppress
lpsinduc
ro
product
cell
prrsvinduc
ro
level
cell
lung
mda
product
vivo
fig
find
provid
evid
antiinflammatori
effect
tylvalosin
link
abil
inhibit
ro
product
oxid
stress
increas
level
proinflammatori
cytokin
balf
note
aliard
persist
elev
mediat
may
induc
enlarg
facilit
entir
focal
inflammatori
reaction
wors
outcom
line
concept
found
mice
challeng
lp
express
larg
amount
proinflammatori
cytokin
balf
compar
neg
control
group
fig
contrast
tylvalosin
pretreat
found
downregul
tnfa
secret
h
lp
challeng
fig
believ
tylvalosin
could
suppress
earli
later
stage
lung
inflamm
result
suggest
protect
effect
tylvalosin
lpsinduc
ali
part
attribut
inhibit
tnfa
member
cxc
chemokin
famili
secret
varieti
cell
type
inflamm
associ
develop
outcom
aliard
thu
prevent
overproduct
may
attenu
lung
inflamm
studi
found
pretreat
mgkg
tylvalosin
level
significantli
decreas
thu
tylvalosin
potenti
util
ali
inflamm
larg
amount
form
action
induc
nitric
oxid
synthas
ino
surpass
physiolog
amount
usual
produc
neuron
nitric
oxid
synthas
nno
endothelium
nitric
oxid
synthas
eno
furthermor
inosderiv
overproduct
appear
ubiquit
mediat
wide
rang
inflammatori
condit
reflect
degre
inflamm
repres
potenti
target
pharmacolog
intervent
inflammatori
diseas
thu
reduct
product
suggest
effect
strategi
treatment
inflammatori
diseas
studi
shown
tylvalosin
suppress
lp
depend
secret
vitro
vivo
fig
exhibit
antiinflammatori
properti
although
detail
mechan
unknown
previou
studi
reveal
analogu
tilmicosin
exhibit
potenti
inhibitori
activ
lpsinduc
product
suppress
express
induc
nitric
oxid
synthas
ino
work
necessari
explor
intrigu
possibl
like
prostaglandin
pg
well
known
import
mediat
inflamm
mainli
synthes
upregul
respons
inflammatori
proinflammatori
mediat
product
influenc
mani
aspect
inflammatori
cascad
present
studi
shown
releas
stimul
lp
effect
attenu
tylvalosin
fig
wide
produc
prostanoid
contribut
fever
pain
swell
inflamm
sinc
tilmicosin
tylosin
decreas
product
downregul
gene
express
vitro
modul
tylvalosin
might
associ
similar
effect
contrari
lakritz
et
al
demonstr
tilmicosin
vitro
appear
reduc
product
lpsstimul
bovin
alveolar
macrophag
without
alter
mrna
express
therefor
unexplor
regulatori
mechan
enzym
need
address
suggest
immedi
product
mediat
cytosol
phospholipas
delay
product
mediat
secretori
phospholipas
hypothes
immunomodul
effect
tylvalosin
contribut
amelior
ali
suppress
well
establish
import
factor
lung
diseas
involv
inflamm
sinc
enzym
repres
famili
distinct
protein
variou
structur
biochem
characterist
determin
particular
role
set
lung
inflamm
proven
quit
challeng
recent
relationship
role
immunoregulatori
effect
tylvalosin
elucid
present
studi
found
activ
ihc
stain
lung
upregul
lp
challeng
fig
elev
protein
express
activ
ali
impli
import
clinic
set
base
cellular
local
substrat
specif
calciumdepend
enzym
possess
relat
activ
identifi
divid
four
group
cytosol
secret
calciumindepend
lipoproteinassoci
elucid
express
profil
biolog
role
group
everi
state
aliard
understand
isoform
suitabl
target
great
valu
develop
therapeut
agent
immunohistochem
analysi
indic
commonli
express
epitheli
bronchial
cell
subbronchi
epitheli
cell
leukocyt
lung
mice
suffer
lp
challeng
howev
express
differ
ctrl
ali
mice
spite
treatment
furthermor
studi
shown
activ
rat
unchang
lowdos
lp
infus
thu
evid
exist
support
role
ali
point
suggest
particip
regul
express
induc
inflammatori
cytokin
endotoxin
consist
six
known
isoform
mammal
among
isoform
contribut
pathogenesi
varieti
inflamm
diseas
attract
attent
target
control
eicosanoid
relat
inflamm
current
studi
initi
examin
potenti
util
express
intermedi
biomark
ali
chemoprevent
trial
end
examin
express
enzym
lung
normal
lp
challeng
mice
treat
tylvalosin
expect
overexpress
epitheli
bronchial
cell
subbronchi
epitheli
cell
leukocyt
lp
challeng
howev
tylvalosin
mgkg
ig
treatment
significantli
downregul
effect
stimul
lp
dosedepend
manner
follow
ali
attenu
thu
result
present
work
put
forward
enzym
target
ali
therapi
futur
cytokin
oxid
stress
also
capabl
induc
express
lung
epitheli
cell
airway
smooth
muscl
cell
lung
fibroblast
consequ
downexpress
might
relat
tylvalosin
immunomodul
product
cytokin
ro
discuss
addit
data
tylvalosin
suppress
lpsinduc
inflammatori
cell
recruit
activ
mous
model
also
support
conclus
sinc
play
major
role
neutrophil
function
inflammatori
infecti
diseas
clinic
set
synthes
within
cytosol
form
inact
enzym
activ
transloc
membran
golgi
endoplasm
reticulum
nuclear
envelop
calciumdepend
manner
phosphoryl
activ
three
serin
residu
significantli
enhanc
activ
repres
mechan
cell
regul
enzym
function
studi
phosphoryl
examin
ihc
stain
expect
lp
induc
phosphoryl
mainli
overexpress
epitheli
bronchial
cell
subbronchi
epitheli
cell
howev
tylvalosin
mgkg
ig
treatment
significantli
downregul
phosphoryl
activ
dosedepend
manner
follow
ali
attenu
thu
inhibit
activ
may
one
crucial
protect
mechan
tylvalosin
lpsinduc
ali
inhibit
express
activ
activ
may
diminish
format
inflammatori
mediat
result
reduc
inflammatori
manifest
may
regul
releas
oxygen
radic
also
particip
endotheli
damag
thu
type
may
suitabl
target
enzym
develop
inhibitori
therapeut
agent
treatment
inflammatori
disord
includ
ali
accumul
evid
indic
work
concert
induc
eicosanoid
format
differ
mammalian
cell
mani
isoform
express
lung
play
signific
role
human
inflammatori
lung
diseas
aliard
condit
elev
amount
found
balf
lung
tissu
seem
promis
therapeut
target
furthermor
present
studi
indic
increas
express
coloc
area
intens
inflamm
exist
posit
correl
increas
level
poor
clinic
outcom
also
known
clone
mous
tissu
howev
preliminari
inform
avail
biochem
properti
noth
known
function
role
ihc
analysi
show
express
epitheli
bronchial
cell
inflammatori
cell
subbronchi
epitheli
leukocyt
knowledg
first
studi
show
express
pattern
mous
lung
ali
express
significantli
increas
lung
lp
challeng
howev
mechan
increas
remain
unclear
instead
tylvalosin
mgkg
ig
treatment
revers
effect
significantli
exact
role
enzym
elucid
better
understand
regul
level
plasma
balf
normal
circumst
aliard
bring
superior
strategi
therapeut
intervent
involv
ali
lead
develop
novel
prodrug
liposom
base
drug
deliveri
system
specif
activ
degrad
diseas
tissu
caus
sitespecif
releas
associ
encapsul
drug
convers
strategi
prevent
activ
concomit
aa
eicosanoid
gener
also
attract
attent
conclus
though
mechan
obscur
decreas
activ
downregul
express
well
activ
lung
might
one
clue
understand
antiinflammatori
properti
tylvalosin
fact
point
famili
potenti
therapeut
target
ali
studi
shown
tylvalosin
abl
inhibit
replic
differ
prrsv
isol
fig
warrant
current
studi
vivo
vitro
viru
grown
select
simian
cell
line
cell
prrsv
entri
cell
might
occur
microfilamentdepend
endocyt
mechan
low
ph
necessari
proper
viru
uncoat
shown
tylvalosin
abl
rais
endosom
ph
may
import
mechan
inhibit
prrsv
replic
although
factor
may
also
involv
prrsv
challeng
model
sever
pneumonia
character
cranioventr
distribut
lobular
purplecolor
consolid
diffus
tancolor
mottl
major
lung
irregular
indistinct
border
happen
piglet
nonmed
challeng
group
data
shown
may
potenti
ali
model
agreement
result
mice
studi
tylvalosin
treatment
attenu
piglet
lung
score
addit
prrsv
strain
hn
challeng
signific
impact
bw
gain
impact
becam
appar
inspect
longer
time
period
infect
day
pi
fig
contrast
tylvalosin
treatment
revers
bodi
weight
drop
model
prrsv
challeng
caus
longlast
high
fever
piglet
fig
downmodul
tylvalosin
rectal
temperatur
challeng
found
white
leghorn
fever
model
induc
lp
mgkg
ip
tylvalosin
also
restrain
bodi
temperatur
closer
normal
data
shown
result
indic
tylvalosin
seem
exhibit
extens
thermoregul
vivo
pathogen
consequ
immunolog
respons
piglet
prrsv
directli
relat
viral
load
acut
infect
reflect
viral
titer
blood
present
studi
tylvalosin
treatment
significantli
reduc
viral
load
might
due
antivir
effect
rapid
absorpt
wide
distribut
properti
tissu
data
indic
prrsvinduc
piglet
model
use
studi
ali
evalu
medic
efficaci
character
natur
inhibitori
effect
tylvalosin
proinflammatori
mediat
product
ro
product
activ
express
well
lp
prrsinduc
lung
injuri
examin
effect
tylvalosin
activ
nfkb
signal
pathway
nfkb
pathway
consid
play
pivot
role
pathogenesi
lpsinduc
ali
prrsv
discuss
heterodim
nfkb
compon
mostli
normal
retain
cytoplasm
inact
form
associ
inhibitor
kb
ikb
protein
wide
varieti
stimuli
caus
phosphoryl
ikb
process
follow
protein
ubiquitin
subsequ
degrad
phosphoryl
induc
degrad
ikb
inhibitor
enabl
nfkb
dimer
enter
nucleu
activ
specif
target
gene
express
studi
observ
inhibitori
effect
tylvalosin
lpsinduc
nfkb
activ
shown
western
blot
immunohistochem
result
fig
report
lp
stimul
product
reactiv
oxygen
elev
enzym
activ
activ
redoxsensit
signal
cascad
includ
nfkb
trigger
elev
express
proinflammatori
mediat
lead
acut
lung
injuri
result
suggest
tylvalosin
reduc
lpsinduc
inflamm
probabl
via
inactiv
ro
blunt
redoxsensit
inflammatori
signal
nfkb
sinc
nfkb
pathway
play
central
role
prrsv
pathogenesi
underli
protect
mechan
tylvalosin
piglet
presum
case
conclus
present
studi
first
time
show
tylvalosin
play
potent
antiinflamm
antioxid
role
lp
prrsvinduc
cell
anim
model
may
due
inhibit
activ
nfkb
pathway
tylvalosin
attenu
lpsinduc
inflamm
lung
injuri
includ
reduct
lung
wd
ratio
inhibit
protein
level
mpo
express
activ
inflammatori
cell
aggreg
balf
histolog
examin
show
tylvalosin
significantli
amelior
tissu
injuri
improv
lung
liver
morpholog
tylvalosin
treatment
reduc
product
proinflammatori
mediat
induc
lp
product
ro
induc
lp
prrsv
enzym
activ
degre
immunohistochem
stain
significantli
reduc
tylvalosin
pretreat
result
impli
potenti
role
manag
ali
furthermor
demonstr
tylvalosin
inhibit
nfkb
activ
lpsinduc
ali
piglet
model
administr
tylvalosin
revers
fluctuat
rectal
temperatur
normal
level
improv
growth
perform
reduc
lung
score
might
involv
antivir
effect
well
inhibit
nfkb
activ
ro
product
therefor
tylvalosin
may
consid
potenti
agent
prevent
ali
futur
also
comprehens
studi
need
clinic
applic
